Who are Rapamune's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Afinitor, Torisel, Afinitor, ZOTAROLIMUS, SIROLIMUS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sirolimus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Rapamune — Competitive Intelligence Brief

Rapamune (sirolimus) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mTOR Inhibitor Immunosuppressant [EPC]. Area: Oncology.

marketed mTOR Inhibitor Immunosuppressant [EPC] Serine/threonine-protein kinase mTOR Oncology Live · refreshed every 30 min

Target snapshot

Rapamune (sirolimus) — Pfizer. Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rapamune TARGET	sirolimus	Pfizer	marketed	mTOR Inhibitor Immunosuppressant [EPC]	Serine/threonine-protein kinase mTOR	1999-01-01
Afinitor	everolimus	Novartis	marketed	Kinase Inhibitor [EPC]	Serine/threonine-protein kinase mTOR	2009-01-01
Torisel	temsirolimus	Pfizer	marketed	Kinase Inhibitor	Serine/threonine-protein kinase mTOR	2007-01-01
Afinitor	Afinitor	Central European Society for Anticancer Drug Research	marketed		Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR
ZOTAROLIMUS	ZOTAROLIMUS		phase 3	zotarolimus	Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR
SIROLIMUS	SIROLIMUS		marketed	mTOR Inhibitor Immunosuppressant [EPC]	mTOR	1999-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-07-01 — Afinitor · 9006224 · Method of Use · US
2029-02-14 — Rapamune · 8911786 · Formulation · US
2030-04-15 — Rapamune · 10206887 · Formulation · US
2036-03-05 — Rapamune · 12061183 · Formulation · US
2036-03-05 — Rapamune · 10705070 · Formulation · US
2036-06-29 — Rapamune · 10973806 · Method of Use · US
2036-06-29 — Rapamune · 12133844 · Method of Use · US
2040-10-28 — Rapamune · 11497737 · Formulation · US

Sponsor landscape (mTOR Inhibitor Immunosuppressant [EPC] class)

· 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rapamune — Competitive Intelligence Brief. https://druglandscape.com/ci/sirolimus. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab